Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer's Disease Differential Diagnosis

Autores de IIS La Fe

• María Del Carmen Peña Bautista

  Autor

• Lourdes Álvarez Sánchez

  Autor

• Ana Isabel Cuevas Jimenez

  Autor

• 

  Miguel Baquero Toledo

  Autor

• Máximo Vento Torres

  Autor

• David Hervás Marín

  Autor

• 

  María Consuelo Cháfer Pericás

  Autor

Participantes ajenos a IIS La Fe

• Durand, Thierry
• Vigor, Claire

Grupos

• Perinatología

Abstract

Background: Differential diagnosis of Alzheimer's disease (AD) is a complex task due to the clinical similarity among neurodegenerative diseases. Previous studies showed the role of lipid peroxidation in early AD development. However, the clinical validation of potential specific biomarkers in minimally invasive samples constitutes a great challenge in early AD diagnosis. Methods: Plasma samples from participants classified into AD (n= 138), non-AD (including MCI and other dementias not due to AD) (n= 70) and healthy (n= 50) were analysed. Lipid peroxidation compounds (isoprostanes, isofurans, neuroprostanes, neurofurans) were determined by ultra-performance liquid chromatography coupled with tandem mass spectrometry. Statistical analysis for biomarkers' clinical validation was based on Elastic Net. Results: A two-step diagnosis model was developed from plasma lipid peroxidation products to diagnose early AD specifically, and a bootstrap validated AUC of 0.74 was obtained. Conclusion: A promising AD differential diagnosis model was developed. It was clinically validated as a screening test. However, further external validation is required before clinical application.

Keywords

• plasma; lipid peroxidation; Alzheimer's disease; differential diagnosis; clinical validation